Sessa Capital IM, L.P.

Position in SABS — SAB Biotherapeutics, Inc.

CIK 1595849 NEW YORK, NY

Position in SABS

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$8,420,090

+$197,861 QoQ

Shares Held

2,198,457

0.0% QoQ

Ownership

2.88%

of shares outstanding

% of Portfolio

0.16%

of 13F equity value

Holder Rank

#12

of 76 holders

Holding Since

Mar 2024

9 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Sessa Capital IM, L.P. holds $87,007,647 across 4 Biotechnology names. SABS ranks #3 (9.7% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	FTRE	Fortrea Holdings Inc.	4,593,550	$43,271,241
2	LXRX	Lexicon Pharmaceuticals, Inc.	17,912,961	$27,944,219
3	SABS	SAB Biotherapeutics, Inc. This page	2,198,457	$8,420,090
4	RNA	Atrium Therapeutics, Inc.	551,391	$7,372,097

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$8,420,090	2,198,457	0.0%	Shares	Sole	2026-05-15
2025-12-31	$8,222,229	2,198,457	0.0%	Shares	Sole	2026-02-17
2025-09-30	$4,418,898	2,198,457	+379.5%	Shares	Sole	2025-11-14
2025-06-30	$804,592	458,457	0.0%	Shares	Sole	2025-08-13
2025-03-31	$623,501	458,457	0.0%	Shares	Sole	2025-05-15
2024-12-31	$1,739,385	458,457	0.0%	Shares	Sole	2025-02-14
2024-09-30	$1,237,833	458,457	0.0%	Shares	Sole	2024-11-12
2024-06-30	$1,421,216	458,457	0.0%	Shares	Sole	2024-08-14
2024-03-31	$2,081,394	458,457	—	Shares	Sole	2024-05-15
No filing history on record for this holder in this stock.